Barclays PLC Cytek Biosciences, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 215,424 shares of CTKB stock, worth $926,323. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,424
Previous 201,359
6.99%
Holding current value
$926,323
Previous $1.12 Million
25.18%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CTKB
# of Institutions
151Shares Held
74MCall Options Held
1KPut Options Held
0-
Black Rock Inc. New York, NY17.1MShares$73.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$50.4 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD8.25MShares$35.5 Million1.27% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$28.6 Million1.65% of portfolio
-
State Street Corp Boston, MA4.51MShares$19.4 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $579M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...